HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mandatory Recall Guidance Positions FDA For ‘Robust’ Use Of Authority

This article was originally published in The Rose Sheet

Executive Summary

Final guidance on mandatory recall authority under FSMA specifies how FDA allows firms opportunities for voluntary recalls and evidence it may consider when deciding whether to mandate a recall. But a consumer advocacy group critical of FDA says the guidance adds nothing for protecting public health.

You may also be interested in...



Melatonin Dose Study, Steroid Warning Show Both Sides Of Coin For US Supplement Industry Image

Separate criticisms show opposite sides of the coin of public perception constantly flipping for businesses large and small making and marketing supplements available in US.

During Recalls, Prepare For 'Blood In The Water' Response From Plaintiffs' Bar

Consumer health marketers’ immediate internal communication and outreach to consumers often provides evidence to plaintiffs’ lawyers, says attorney Victoria Calhoon. Plaintiffs' lawyers “smell blood in the water” once a recall is made public but companies can defend against litigation.

Cosmetics Recalls For August-October Period Have One Familiar Thing In Common: All Were Voluntary

Under current cosmetics regulations FDA does not have the authority to order product recalls, as it does in the dietary supplement space, for example. Voluntary cosmetic recalls have been typically light in recent months, most often citing microbiological issues.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel